CD20

DGAP-News: Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Retrieved on: 
星期二, 八月 24, 2021
Constellation, FC, Spleen, Food, Lymph, Lymphoid leukemia, Safety, Thrombocytopenia, Bone marrow, Tafasitamab, Aplastic anemia, Dor, AES, Tumor lysis syndrome, U.S. Securities and Exchange Commission, Communication, Compliance, ORR, Anemia, Psoriasis, Risk, Clinical trial, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Industry, Liver, FSE, Judgement, Lenalidomide, Lymphoma, ASCT, Antibody, Immunotherapy, Development, Degenerative disease, NASDAQ, Health Canada, DLBCL, Apoptosis, FDA, Rituximab, Janssen Pharmaceuticals, PFS, LLC, Progression-free survival, HCD, Cancer, Infection, ADCP, Neutropenia, CD20, Patient, Annual report, ADCC, Vaccine, Pharmaceutical industry, Medical imaging, Online shopping, Diffuse Large B-cell Lymphoma (DLBCL), L-MIND, RE-MIND, Minjuvi(R) (tafasitamab), MorphoSys, DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), L-MIND, RE-MIND, MINJUVI(R) (TAFASITAMAB), MORPHOSYS

Incyte and MorphoSys share global development rights for tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outside the United States.

Key Points: 
  • Incyte and MorphoSys share global development rights for tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outside the United States.
  • Removal of the conditions from the Notice of Compliance is contingent upon verification and description of clinical benefit in a confirmatory trial(s).
  • Adverse events (AEs) reported included infusion-related reactions, serious or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia, infections and tumour lysis syndrome.
  • The study compares real-world response data of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received lenalidomide monotherapy with the efficacy outcomes of the tafasitamab-lenalidomide combination, as investigated in MorphoSys' L-MIND trial.

Incyte Announces Health Canada Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Retrieved on: 
星期二, 八月 24, 2021
Acute leukemia, FC, AG, Spleen, Medical Affairs Bureau, Research, Oncology, Food, Lymph, Lymphoid leukemia, Safety, Solution, Thrombocytopenia, Bone marrow, Aplastic anemia, Dor, AES, University, Tumor lysis syndrome, Therapy, U.S. Securities and Exchange Commission, Compliance, ORR, Anemia, Clinical trial, Adult, Liver, Lenalidomide, B-cell lymphoma, Lymphoma, ASCT, Health Canada, DLBCL, Apoptosis, FDA, Security (finance), Rituximab, Company, PFS, Annual report, Progression-free survival, HCD, Infection, ADCP, Neutropenia, Marketing, CD20, University of British Columbia, Patient, ADCC, Vaccine, Pharmaceutical industry, Medical imaging, Online shopping, Wood drying

Incyteand MorphoSys share global development rights to tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outsidethe United States.

Key Points: 
  • Incyteand MorphoSys share global development rights to tafasitamab; Incyte has exclusive commercialization rights to tafasitamab outsidethe United States.
  • Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi in the U.S. and is marketed by Incyte under the brand name Minjuvi in Canada.
  • Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.
  • Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma.

Molecular Templates, Inc. Reports Second Quarter 2021 Financial Results

Retrieved on: 
星期四, 八月 12, 2021
Biology, Coley's toxins, Forward-looking statement, Doctor of Philosophy, Pharmacodynamics, Bristol Myers Squibb, Index (publishing), Private Securities Litigation Reform Act, Tumor microenvironment, Multiple myeloma, American Association, Patient, COVID-19, TIGIT, American Association for Cancer Research, NK, IND, GLOBE, Chief scientific officer, SEC, Research, Cell, Vertex, Conference, EC50, Investment, Breast cancer, PD-L1, CD20, ETB, MTD, PD, CD45, Association, Neoplasm, Cancer, Nasdaq, Safety, AACR, Therapy, Ladenburg, ETB (company), Vaccine, Animal, Iron ore, Gasoline, Pharmaceutical industry, Risk management

AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.

Key Points: 
  • AUSTIN, Texas, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, Molecular Templates, or MTEM), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the second quarter of 2021.
  • MTEM provided a corporate update and participated in 1-on-1 investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, which took place July 13-14, 2021.
  • The net loss attributable to common shareholders for the second quarter of 2021 was $15.6 million, or $0.28 per basic and diluted share.
  • Revenues for the second quarter of 2021 were $15.1 million, compared to $6.9 million for the same period in 2020.

IGM Biosciences Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 八月 9, 2021
Investment, R, IGM, U.S. Securities and Exchange Commission, Infection, Toxicity, Intellectual property, GLOBE, COVID-19, FDA, Trial of the century, Mouse, Nature, University of Texas Medical Branch, Nasdaq, Toxic leukoencephalopathy, University of Texas System, GAAP, Industry, DR5, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Variant, University, Immunoglobulin M, Lymphatic system, Gilead Sciences, Severe acute respiratory syndrome coronavirus 2, Research and development, Risk, Patient, SEC, Forty-seven rōnin, NHL, CD20, Safety, G&A, Food, Immunoglobulin G, IND, Administration, Security (finance), Stanford University, Company, FOLFIRI, Fine chemical, Pharmaceutical industry, Medical device, Cryptocurrency

MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent developments.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the second quarter ended June 30, 2021 and provided an update on recent developments.
  • IGM expects to report initial data from the dose escalation portion of the Phase 1 trial in 2021.
  • In June 2021, IGM announced IGM-6268, which represents the expansion of the Companys IgM platform into infectious diseases.
  • Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies.

Follicular Lymphoma Drug Landscape Report 2021 - ResearchAndMarkets.com

Retrieved on: 
星期五, 八月 6, 2021
Pharmaceutical, Health, Oncology, Route of administration, PD-1, Clinical trial, Cell, MorphoSys, Pembrolizumab, B-cell lymphoma, Administration, II, III, Ligand, FC, ADCP, Immune system, Apoptosis, Lymphocyte, Lymphatic system, Tafasitamab, CD3, ADCC, Discovery, Follicular lymphoma, News, Therapy, PD-L1, Route, CD20, Tissue, Pharmaceutical industry, Vaccine

This Follicular lymphoma - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular lymphoma pipeline landscape.

Key Points: 
  • This Follicular lymphoma - Pipeline Insight, 2021 provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Follicular lymphoma pipeline landscape.
  • This segment of the Follicular lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • This segment of the report provides insights about the different Follicular lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • Follicular lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Retrieved on: 
星期三, 八月 4, 2021
Drugs, Orphan drugs, Health care, Health sciences, Rituximab, CD20, Breakthrough therapy

OSLO, Norway, Aug. 4, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).

Key Points: 
  • OSLO, Norway, Aug. 4, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).
  • The Company will host a live webcast and Q&A on Thursday, 5 August 2021, at 08.30 CEST.
  • A link to the webcast will beavailable in the afternoon on Wednesday, 4 August on www.nordicnanovector.com .
  • In addition, the Company confirms it will invest no further funds in its Archer-1 Phase 1b trial investigating Betalutin in combination with rituximab in 2nd-line FL.

Nordic Nanovector Provides Update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular Lymphoma

Retrieved on: 
星期三, 八月 4, 2021
Drugs, Orphan drugs, Health care, Health sciences, Rituximab, CD20, Breakthrough therapy

OSLO, Norway, Aug. 3, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).

Key Points: 
  • OSLO, Norway, Aug. 3, 2021 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) provides an update on the timeline for PARADIGME, its ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL).
  • The Company will host a live webcast and Q&A on Thursday, 5 August 2021, at 08.30 CEST.
  • A link to the webcast will beavailable in the afternoon on Wednesday, 4 August on www.nordicnanovector.com .
  • In addition, the Company confirms it will invest no further funds in its Archer-1 Phase 1b trial investigating Betalutin in combination with rituximab in 2nd-line FL.

Study from The Leukemia & Lymphoma Society Shows COVID-19 Vaccine Is Safe But 25% Of Blood Cancer Patients Do Not Produce Detectable Antibodies

Retrieved on: 
星期四, 七月 22, 2021
Medical specialties, Clinical medicine, Medicine, Immunology, Immune system, Rituximab, Monoclonal antibody, Cancer, COVID-19, CD20, Vaccine, Antibody

"But not everyone will be protected, and blood cancer patients are at increased risk of serious illness and death from COVID-19.

Key Points: 
  • "But not everyone will be protected, and blood cancer patients are at increased risk of serious illness and death from COVID-19.
  • We encourage blood cancer patients to take every measure to protect themselves from COVID-19 by getting vaccinated and continuing to take preventative precautions.
  • LLS estimates that nearly 250,000 blood cancer patients in the U.S. will not have detectable antibodies following COVID-19 vaccination.
  • Many of these patients were treated with anti-CD20 antibodies such as rituximab, which eliminates B-cells that make antibodies.

Cellectis’ Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities

Retrieved on: 
星期一, 六月 14, 2021
Branches of biology, Biology, Biotechnology, Cellectis, Life sciences, Molecular biology, Gene delivery, Electroporation, CD20, Sickle cell disease, André Choulika

To watch a replay of all Cellectis Innovation Days episodes, click here .

Key Points: 
  • To watch a replay of all Cellectis Innovation Days episodes, click here .
  • Additionally, we are thrilled to announce Cellectis .HEAL genome surgery HSC platform, a new arm of Cellectis which focuses on monogenic diseases, like Sickle Cell Anemia.
  • Cellectis outlines four new UCART preclinical programs, targeting solid tumors
    A derivative of UCART22, that newly includes an additional CAR targeting CD20.
  • Cellectis electroporation platform is designed for rapid gene editing delivery optimization for any cell and payload type, especially for gene editing.

Acepodia Presents Data on its Allogeneic Natural Killer-Like Gamma-Delta T Cell Therapy, ACE1831, in Development for Hematological Cancers

Retrieved on: 
星期三, 五月 19, 2021
Medical specialties, Branches of biology, Immune system, Clinical medicine, Natural killer cell, Gamma delta T cell, T cell, CD20, Cancer immunotherapy, Immunotherapy

Gamma delta T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies.

Key Points: 
  • Gamma delta T cells have characteristics of both the innate and adaptive immune systems that make them an ideal chassis for the development of cell therapies.
  • ACE1831 targets CD20-expressing hematological cancers using anti-CD20 antibody conjugated gamma delta T cells.
  • The company\xe2\x80\x99s next generation allogeneic, off-the-shelf cell therapies are based on a proprietary NK cell line (oNK) and allogneic NK-like gamma delta T cells that have been selected for their potent anti-tumor activity.
  • Its lead product candidate, ACE1702, is the first antibody-conjugated NK cell therapy in clinical development for the treatment of HER2-expressing solid tumors.